NCT03149250

Brief Summary

The study aims to investigate the impact of preeclampsia on hemostasis.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Sep 2017

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 3, 2017

Completed
8 days until next milestone

First Posted

Study publicly available on registry

May 11, 2017

Completed
4 months until next milestone

Study Start

First participant enrolled

September 1, 2017

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2017

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2018

Completed
Last Updated

August 22, 2017

Status Verified

August 1, 2017

Enrollment Period

4 months

First QC Date

May 3, 2017

Last Update Submit

August 17, 2017

Conditions

Keywords

Aggregometry

Outcome Measures

Primary Outcomes (1)

  • Area under the aggregation curve in the ADPtest of the Multiple Electrode Aggregometry

    ADP induced platelet aggregation

    Between 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study

Secondary Outcomes (3)

  • Area under the aggregation curve in the ASPItest of the Multiple Electrode Aggregometry

    Between 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study

  • Area under the aggregation curve in the TRAPtest of the Multiple Electrode Aggregometry

    Between 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study

  • Parameters of plasmatic coagulation system

    Between 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study

Study Arms (3)

Pregnant Preeclampsia

Pregnant between 35th and 40th week of pregnancy Preeclampisa Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling in the context of routinely performed blood sampling

Diagnostic Test: Aggregometry, Monitoring of plasmatic hemostasis

Pregnant No-Preeclampsia

Control Group 1 Pregnant between 35th and 40th week of pregnancy No Preeclampsia Healthy Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling in the context of routinely performed blood sampling

Diagnostic Test: Aggregometry, Monitoring of plasmatic hemostasis

Not Pregnant

Control group 2 Healthy and not pregnant control group Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling.

Diagnostic Test: Aggregometry, Monitoring of plasmatic hemostasis

Interventions

Multiple Electrode Aggregometry using the Multiplate system Coagulation factor analyses (FXIII, FVIII, vWF) Parameters of conventional coagulation testing (aPTT, INR, Platelet count)

Not PregnantPregnant No-PreeclampsiaPregnant Preeclampsia

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsFemale (Study cohort is pregnant, control group should be female too)
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

Pregnant patients suffering from preeclampsia, n = 20 Control group 1: Healthy pregnant patients, not suffering from preeclampsia, n=20 Control group 2: Healthy woman (age between 18 and 40y) that are not pregnant

You may qualify if:

  • Platelet count \> 100 / nll
  • In study group and control group 1: Week of Pregnancy: 35-40
  • in control group 2: healthy, not pregnant woman

You may not qualify if:

  • Hereditary coagulopathy
  • Missing content of the patient / proband
  • Eclampsia
  • HELLP syndrome
  • CRP \> 1 mg/dl
  • Fever (\> 38°C)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Blood Coagulation Disorders

Condition Hierarchy (Ancestors)

Hematologic DiseasesHemic and Lymphatic Diseases

Study Officials

  • Christian F Weber, MD, PhD

    Goethe University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Christian F Weber, MD, PhD

CONTACT

Niels Loechelt, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. Dr. med. Christian F. Weber

Study Record Dates

First Submitted

May 3, 2017

First Posted

May 11, 2017

Study Start

September 1, 2017

Primary Completion

December 31, 2017

Study Completion

February 1, 2018

Last Updated

August 22, 2017

Record last verified: 2017-08

Data Sharing

IPD Sharing
Will not share